Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
October 13, 2026

Tucatinib / Tukysa for First-Line Maintenance Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer as of October 2026

MARA Rating Company October 13, 2026

Hyrnuo / Sevabertinib for First-Line Locally Advanced or Metastatic Non-Squamous NSCLC with HER2 (ERBB2) Tyrosine Kinase Domain Activating Mutations as of October 2026

MARA Rating Company October 13, 2026

Fayuvi / Rebisufligene etisparvovec for mucopolysaccharidosis type IIIA as of October 2026

MARA Rating Company October 13, 2026

Hovilpri / Pritelivir for Herpes Simplex Virus Mucocutaneous Lesions in Immunocompromised Adults as of October 2026

MARA Rating Company October 13, 2026

Jaypirca / Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Without a Known 17p Deletion as of October 2026

MARA Rating Company October 13, 2026

Gazyva / Obinutuzumab for Frequently Relapsing or Steroid-Dependent Childhood-Onset Idiopathic Nephrotic Syndrome as of October 2026

MARA Rating Company October 13, 2026

Aqneursa / Levacetylleucine for Ataxia in Patients with Ataxia-Telangiectasia as of October 2026

MARA Rating Company October 13, 2026

Welireg / Belzutifan for Advanced Clear-Cell Renal Cell Carcinoma After PD-1/PD-L1 Therapy as of October 2026

MARA Rating Company October 13, 2026

Tecentriq / Atezolizumab for Adjuvant Stage III Mismatch Repair–Deficient Colon Cancer with a Fluoropyrimidine and Oxaliplatin as of October 2026

MARA Rating Company October 13, 2026

Ameluz / Aminolevulinic acid hydrochloride for Superficial Basal Cell Carcinoma Treated with Red-Light Photodynamic Therapy as of October 2026

MARA Rating Company October 13, 2026